Filing Flows › Senti Biosciences Holdings (SNTI) › Q2 2026 › vs Q1 2026
Senti Biosciences Holdings (SNTI) Q2 2026 vs Q1 2026 (quarter over quarter)
Senti Biosciences Holdings's revenue rose $1K (+6%) from $16K in Q1 2026 to $17K in Q2 2026.
Senti Biosciences Holdings, Q2 2026: revenue $17K, net loss $12.8M, operating cash flow −$14.2M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $17K | $16K | $1K | +6% |
| Other income, net | $1.7M | $395K | $1.3M | +340% |
| Net loss | $12.8M | $4.2M | $8.5M | +202% |
| Costs & expenses | $14.5M | $4.6M | $9.9M | +213% |
| Operating costs | $14.5M | $4.6M | $9.9M | +213% |
| Operating cash sources | $16.0M | $9.5M | $6.5M | +68% |
| Depreciation | $667K | $688K | −$21K | -3% |
| Share-based compensation | $1.0M | $1.3M | −$267K | -20% |
| Cash used in operations | $14.2M | $7.5M | $6.8M | +90% |
| Net loss absorbed | $12.8M | $4.2M | $8.5M | +202% |
| Working capital & other | $3.2M | $5.3M | −$2.0M | -39% |
Questions
How much did Senti Biosciences Holdings's revenue grow quarter over quarter in Q2 2026?
Senti Biosciences Holdings's revenue rose $1K (+6%) from $16K in Q1 2026 to $17K in Q2 2026.